vortioxetine (Trintellix)
Jump to navigation
Jump to search
Introduction
Brintellix (vortioxetine) and Brilinta (ticagrelor) name confusion.[3] Name changed to Trintellix[4]
Indications
Dosage
Tabs: 5, 10, 15 & 20 mg
Adverse effects
Mechanism of action
- serotonin reuptake inhibition
- serotonin receptor 5-HT1A agonist
- partial agonist serotonin receptor 5-HT1B
- antagonist serotonin receptor 5-HT3A
- antagonist serotonin receptor 5-HT7
More general terms
References
- ↑ FDA News Release: Sept. 30, 2013 FDA approves new drug to treat major depressive disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370416.htm
- ↑ Prescriber's Letter 20(12): 2013 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=291206&pb=PRL Comparison of Antidepressants (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 FDA MedWatch. July 30, 2015 Brintellix (vortioxetine) and Brilinta (ticagrelor): Drug Safety Communication - Name Confusion. https://mail.google.com/mail/u/0/?tab=wm#inbox/14edfa25fc57b461
- ↑ 4.0 4.1 Brooks M From Brintellix to Trintellix : Drug's Name Changes for Safety. Medscape Medical News. May 2, 2016 http://www.medscape.com/viewarticle/862760